Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Nevada 11- ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2022 was $8.6 million, a 4.2% increase from Q4 2021 [13] - Annual recurring revenue (ARR) reached $7.9 million, up almost 8% sequentially and 35% year-over-year [14] - Net loss for Q4 was $438,000 or $0.02 per share, compared to a loss of $89,000 in the prior year [20] - Total revenue for the full fiscal year 2022 increased 3.7% to $32.9 million compared to $31.8 million in fiscal 2021 [22] - Net loss for fiscal 2022 was $1.6 million or $0.06 per share, compared to a loss of $207,000 in the prior year [27] Business Line Data and Key Metrics Changes - Platform subscription revenue increased 32% to $1.9 million in Q4, driven by a net increase in platform ARR bookings [13] - Transaction revenue decreased slightly to $6.7 million from $6.8 million in Q4 2021 [15] - Total platform deployments as of June 30 were 733, a net increase of 180 deployments or 33% from a year ago [23] - Gross margin for the platform business was 87.3%, while transaction business gross margin increased to 24.5% [18][25] Market Data and Key Metrics Changes - The company ended Q4 with 1,213 active customers, a net increase of 81 from the same period a year ago [15] - Renewal rates remained strong in the high 90s, with net renewal rates over 110% for the year [9] Company Strategy and Development Direction - The company aims to accelerate growth through organic means and acquisitions, with a focus on enhancing the sales force and product strategy [33] - A new product, Curedatis, is set to launch in October, targeting the pharmacovigilance market with a total addressable market (TAM) of approximately $650 million [56] - The company is reevaluating its pricing and sales strategy for Article Galaxy Scholar to improve customer take rates [55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving adjusted EBITDA and cash flow positive for fiscal year 2023, with expectations of overall topline growth [29] - Early signs of growth in the transaction business were noted, with potential for double-digit overall topline growth in Q1 2023 [30] - Management acknowledged challenges in the transaction revenue but indicated improvements throughout the fiscal year [23] Other Important Information - Total operating expenses for fiscal 2022 were $13.6 million, up from $10.5 million in the prior year, primarily due to increased technology and product development costs [26] - The company has no long-term debt or liabilities and ended Q4 with $10.6 million in cash and cash equivalents [28] Q&A Session Summary Question: How has Galaxy Scholar performed? - Management noted disappointing customer take rates for Article Galaxy Scholar but plans to split it into freemium and premium versions to drive transaction revenues [55] Question: What are the expectations for the new product Curedatis? - Curedatis is expected to generate a few hundred thousand in revenue in FY2023, with a conservative approach to its sales forecast [56] Question: Can you discuss the sales model for the pharmacovigilance product? - The product will be sold through the current sales force, with potential for a dedicated sales team if traction is achieved [67] Question: What is the approach to M&A funding? - The company plans to use a mix of cash and potentially seller notes for acquisitions, avoiding equity due to current stock price concerns [71] Question: How high is the quota attainment rate in sales? - Management indicated that all new sales personnel met their quotas, and there is no capacity problem, only a need to fill the sales pipeline [72]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) N ...

Research Solutions, Inc. (NASDAQ:RSSS) Q3 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Steven Hooser - IR Roy Olivier - President and CEO Bill Nurthen - CFO Conference Call Participants Allen Klee - Maxim Group Peter Rabover - Artko Capital Richard Baldry - ROTH Capital Operator Good afternoon, everyone. And thank you for participating in today’s conference call to discuss Research Solutions Financial and Operating Results for its Fiscal Third Quarter ended March 31, 2022. As a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter ...

Research Solutions, Inc. (NASDAQ:RSSS) Q2 2022 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants Steven Hooser - IR Roy Olivier - Interim President and CEO Bill Nurthen - CFO Conference Call Participants Allen Klee - Maxim Group Richard Baldry - ROTH Capital Adam Wilk - Greystone Capita Peter Rabover - Artko Capital George Melas - MKH Management Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the tran ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Address not applicable 1 N/A (Address of principal executive offices) (Zip Code) Commission File No. 001-39 ...

Research Solutions, Inc. (NASDAQ:RSSS) Q1 2022 Earnings Conference Call November 11, 2021 5:00 PM ET Company Participants John Beisler - IR, Three Part Advisors Roy Olivier - Interim President and CEO Bill Nurthen - CFO Conference Call Participants Richard Baldry - ROTH Capital Allen Klee - Maxim Scott Bilodeau - Walrus Partners Operator Good afternoon, everyone. And thank you for participating in today’s conference call to discuss Research Solutions Financial and Operating Results for its Fiscal First Quar ...

Research Solutions, Inc. (NASDAQ:RSSS) Q4 2021 Earnings Conference Call September 23, 2021 5:00 PM ET Company Participants John Beisler - IR, Three Part Advisors Roy Olivier - Interim President and CEO Alan Urban - Chief Financial Officer Conference Call Participants Richard Baldry - ROTH Capital Allen Klee - Maxim Group Adam Wilk - Greystone Capital Operator Good afternoon, everyone. And thank you for participating in today’s conference call to discuss Research Solutions Financial and Operating Results for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 000-53501 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Nevada 11- ...